| Related Articles |
Patient derived xenografts as tools in pharmaceutical development.
Clin Pharmacol Ther. 2016 Feb 13;
Authors: Izumchenko E, Meir J, Bedi A, Wysocki PT, Hoque M, Sidransky D
Abstract
Successful drug development in Oncology is grossly suboptimal, manifested by the very low percentage of new agents being developed that ultimately succeed in clinical approval. This poor success is in part due to the inability of standard cell-line xenograft models to accurately predict clinical success and to tailor chemotherapy specifically to a group of patients more likely to benefit from the therapy. Patient-derived xenografts (PDXs) maintain the histopathological architecture and molecular features of human tumors, and offer potential solution to maximize drug development success and ultimately generate better outcomes for patients. Although imperfect in mimicking all aspects of human cancer, PDXs are a more predictable platform for preclinical evaluation of treatment effect and in selected cases can guide therapeutic decision making in the clinic. This manuscript summarizes the current status of PDX models, challenges associated with modeling human cancer and various approaches that have been applied to overcome these challenges and improve the clinical relevance of PDX cancer models. This article is protected by copyright. All rights reserved.
PMID: 26874468 [PubMed - as supplied by publisher]
from #MedicinebyAlexandrosSfakianakis via xlomafota13 on Inoreader http://ift.tt/1RFCynV
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου